San Diego-dependent Viking Therapeutics marked alone as a serious competitor while in the weight loss drug market place in February just after revealing promising info from a mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when specified being a weekly injection and in March the company